RESEARCH TRIANGLE PARK –Memory Pharmaceuticals Corp. is deploying Arthur Suite from Synthematix as part of its chemistry operations, the companies announced Tuesday.
Memory is developing drugs for use in treating central nervous system conditions.
“Synthematix’s Arthur Suite is a unique tool designed to promote innovation and knowledge retention in pharmaceutical discovery,” said Ashok Tehim, director of medicinal chemistry at Memory Pharmaceuticals, in a statement. “Memory Pharmaceuticals selected the Arthur Suite because its reaction planning tools make it much more than just an Electronic Lab Notebook (ELN) product. It allows our chemists to think and plan in new ways.”
Financial terms were not disclosed.
Arthur Suite is designed to assist chemists in searching, data mining, planning and creating synthetic reactions and procedures.